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EDITORIAL 
Physician Use of Beta-Adrenergic Blocking Therapy: 
A Changing Perspective* 
HAROLD L. KENNEDY, MD, MPH, ROBERT S. ROSENSON, MD 
Chicago, Illinois 
Although the merit of beta-adrenergic blocking therapy in the 
treatment of cardiovascular disease has steadily evolved since 
its clinical introduction ~30 years ago (1,2), it remains ome- 
what enigmatic as to why these therapeutic agents are not 
prescribed more widely by North American physicians (3). This 
physician resistance to utilizing beta-blocker therapy, in our 
opinion, is multifaetorial nd has resulted from a combination 
of both scientific and commercial events that occurred in North 
America during the past two decades. This scientific landscape 
is now changing, and it is appropriate to examine the factors 
that color physicians' attitudes regarding this therapeutic class 
of drugs. 
Initially, investigative studies and clinical trials of beta- 
blocker therapy were slow to emerge. In part, this resulted 
from the slow genesis and refinement ofscientific methodology 
regarding clinical trials (4), and in part because the clinical 
introduction of beta-blocker therapy was simultaneously ac- 
companied by (at least in North America) an insidious medical 
concern regarding the adverse ffects of beta-blocker therapy 
(5-7). Despite multicenter randomized clinical trials that de- 
finitively established tile importance ofbeta-blocker therapy as 
an independent preventive therapy in both ischemic heart 
disease and hypertension for decreasing all-cause mortality, 
cardiovascular mortality and sudden death (2,8-10), physician 
prescription of such therapy in North America has remained 
unexpectedly low (3). These practice attitudes have evolved for 
several reasons; prominent among them is a sense of physician 
skepticism concerning the benefits of beta-blocker therapy and 
an exaggerated concern for their adverse ffects. After three 
decades of clinical investigation and >55 trials of beta-blocker 
therapy involving as many as 53,000 patients (11-13), it is both 
appropriate and timely for physicians to reflect and critically 
examine the data that established the merit of beta-blocker 
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therapy in cardiovascular diseases and perhaps reflect on their 
personal perspective and temerity (if any) in prescribing such 
therapy. 
Ethcacy of Beta-Blocker Therapy 
Beta-blocker therapy has been shown to be eiticacious 1) as 
primary preventive therapy in hypertensive patients to reduce 
cardiovascular events and all-cause death (10); 2) as a second- 
ary preventive therapy in acute and post-myocardial infarction 
patients to decrease myocardial reinfarction, total mortality, 
cardiovascular mortality and sudden death (11-13); 3) as a 
moderately tohighly effective ai~tiarrhythmic agent for ventric- 
ular arrhythmias when used as monotherapy or adjuvant 
combined therapy for specific patient subsets (14-18); 4) in 
preventing postoperative atrial fibrillation or flutter in patients 
undergoing coronary artery bypass graft surgery (19,20); 5) in 
the prevention ofsudden death in patients with congenital long 
QT syndrome (21,22); 6) in improving "~ystolic dysfunction m 
idiopathic dilated and ischemic ardiomyopathy (23-27); and 
7) in the therapy of various systemic disease states where 
adrenergic activity itself is deleterious (e.g., thyrotoxicosis, 
Marfan syndrome, dissecting aortic aneurysm, esophageal var- 
ices, essential tremor, alcohol withdrawal) (28-31). Additional 
cardiovascular p eventive benefit seems intuitive from experi- 
mental and clinical data, which have shown that beta-blocker 
therapy 1) decreases platelet aggregation (32-34); 2) decreases 
plaque rupture (32); 3) decreases mean blood velocity and thus 
reduces hear stress in vascular dissection (28,32); 4) decreases 
endothelial permeability to mherogenic low density lipopro- 
teins (35); a,ad 5) decreases atheroma formation in animals 
(32,35). Although these antiatherogenic effects of beta-blocker 
pharmacologic a tion are apparent, definitive clinical evidence 
of this benefit is not forthcoming because no large clinical trial 
directly assessing long-term beta-blocker therapy on athero- 
sclerosis has been performed nor is planned (36). 
Beta-blocker therapy has also been shown to have favorable 
effects on the autonomic nervous ystem by increasing heart 
rate variability indexes that are secondary to increased vagal 
tone, attenuating vagal withdrawal and reducing sympathetic 
beta-receptor stimulation or a combination of such effects 
(37-39). Moreover, in myocardial failure, where elevated 
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catecholamine levels have been associated with myofibrillar 
degeneration a d cardiomyopathy (40, x, down-regulation (re- 
duced numbers) of betal-receptors (41,42) and alteration in 
the G protein complex important in coupling beta-receptors to 
adenylate cyclase (43), it seems rational that beta-adrenergic 
blockade would be beneficial (24). 
Recent clinical data on patients with idiopathic ardiomy- 
opathy have shown that left ventricular dysfunction is im- 
proved by beta-blocker therapy by ameliorating both increased 
neuroendocrine activation and decreased myocardial substrate 
utilization (43) and by blocking sympathetic-induced immune 
abnormalities that reduce cell-mediated immunity and circu- 
lating T cells (44). These latter data support preliminary 
observations from the Metoprolol Dilated Cardiomyopathy 
(MDC) trial (45,46), which found beneficial improvement 
of ejection fraction in those patients without betat-auto- 
antibodies on metoprolol. In the largest (641 patients) pro- 
spective randomized heart failure mortality study of beta- 
blocker therapy published to date, the Cardiac Insufficiency 
Bisoprolol Study (CIBIS) (27) disclosed in subgroup analysis a 
survival benefit of bisoproiol in patients with a diagnosis of 
primary dilated cardiomyopathy. Nonetheless, as recognized 
by ~xperts in the field, previous randomized trials of beta- 
blocker therapy in congestive h art failure (MDC and CIBIS) 
have been underpowered and have not used proper dosage in 
appropriate subsets of patients; therefore, definitive recom- 
mendations have not been established (47). 
Renewed Interest in Beta-Blocker Therapy 
Renewed interest in the merit of beta-blocker therapy for 
cardiovascular diseases has emerged predominantly during the 
past 5 years as a result of diverse clinical developments. One 
surprising development was the findings of the Cardiac Ar- 
rhythmia Suppression Trial (CAST) (48,49), which disclosed 
that class I antiarrhythmic agents were harmful to post- 
myocardial infarction patients for the treatment ofasymptom- 
atic or mildly symptomatic ventricular arrhythmias. These 
presumed proarrhythmic events heightened the anxiety of 
many physicians in prescribing any and all antiarrhythmic 
agents and necessitated a search for efficacious and safe 
long-term sudden death preventive agents to be used in 
post-myocardial infarction patients (50). Whereas physician 
antiarrhythmic drug interest subsequently refocused on the 
class III agents otalol and amiodarone (51-57), there also 
clearly emerged renewed interest in beta-blocker monotherapy 
for such patients (17,18,50). 
Another development i fluencing the perspective ofbeta- 
blocker therapy has resulted from the enlarging population of 
patients with congestive heart failure and their need for 
efficacious pharmacologic therapy. Congestive heart failure 
affects between 1 and 2 million U.S. adults and has a 5- to 
10-year mortality rate ranging from 10% to 70% dependent on
age and severity, and more than half of the mortality in North 
America is by sudden death (58,59). In such patients the 
benefit of beta-blocker therapy was suggested by data from the 
Beta-Blocker Heart Attack Trial (BHAT) (60), which showed 
beta-blocker therapy in post-myocardial infarction patients 
with a history of congestive heart failure to be associated with 
the greatest freedom from cardiovascular events and sudden 
death. These findings were further supported by multivariate 
analyses of the data of the Multicenter Diltiazem Post- 
Infarction Trial (61) and CAST (62), both of which found 
beta-blocker therapy to be an independent and significant 
factor associated with less occurrence of new or worsened 
congestive heact failure in post-myocardial nfarction patients 
with an ejection fraction <-40% or a history of congestive heart 
failure. Moreover, since 1975 there has been accruing evidence 
that beta-01ocker therapy beneficially improves ystolic dys- 
function in patients with idiopathic dilated cardiomyopathy 
(23-27,43,45). The attributes of beta-blocker therapy for both 
ischemic and idiopathic cardiomyopathy appear promising 
enough that the Department ofVeterans Affairs Cooperative 
Studies Program and the National Heart, Lung, and Blood 
Institute are jointly commencing a clinical trial in 1995, the 
Beta-Blocker Evaluation of Survival Trial (BEST), to ,toter- 
mine whether beta-blocker therapy in addition to standard 
medical therapy prolongs the lives of patients with congestive 
heart failure. 
Finally, the development and emergence ofmodern epide- 
miologic techniques ofmeta-analysis have also emphasized the 
merits of beta-blocker therapy by calling attention to the large 
number of randomized long- and short-term clinical trials of 
beta-blocker therapy, the strength of the observations and the 
conclusiveness of the data (I1-13). The consensus from such 
meta-analyses indicates that patients with coronary artery 
disease receiving beta-blocker agents without intrinsic sympa- 
thomimetic activity consistently benefit from statistically signif- 
icant reductions in all-cause mortality, cardiovascular mortal- 
ity, nonfatal cardiac arrest and sudden death, cardiac rupture, 
ventricular fibrillation and myocardial reinfarction (11-13). 
Physician Nonuse of Beta-Blocker Therapy 
The reawakening of interest in beta-blocker therapy for 
preventing cardiovascular events and sudden death and im- 
proving the prognosis of patients with congestive heart failure 
has focused attention on the relative nonuse of beta-blocker 
therapy by North American and English-speaking physicians 
(3). As shown in Table 1, the optional utilization of beta- 
blocker therapy during the past decade by North American 
physicians in post-myocardial nfarction and congestive heart 
failure populations in published clinical trials is dramatically 
lower than that in similar investigation~ i  Scandinavian pop- 
ulations (52,61-71). Low utilization of beta-blocker therapy 
also exists in clinical trials reported from western European 
countries and Mexico (Table 1) (53,72-76). Whereas the use of 
beta-blocker therapy in the studies hown in Table 1 was an 
optional choice of individual physicians, a marked isparity in 
prescribed beta-blocker therapy from North American studies 
(12% to 38%) compared with Scandinavian studies (46% to 
70%) is apparent. Although critics may correctly indicate that 
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Table 1, Optional Use of Beta-Blocker Therapy 
Duration Study Beta-Blocker Usage 
Study (tef. no.) of Study Population Diagnosis (clinical trial) [% (no. of pts)] 
North America 
Pagley et al. (63) 1975-1990 5,480 Acute M! 17-60' 
Lichstein et al. (61) 1983-1986 1,084t Acute M! (MDPIT) 12 (13~) 
Cairns et al. (52) 1986-1988 77 Acute MI (CAMIAT) 32 (25) 
The SOLVD Investigators (64) 1986-1989 2,569 NYHA 11-111 CHF (SOLVD) 8 (197) 
The SOLVD Investigators (65) 1986-1990 4,228 Asymptomatic CHF (SOLVD) 24 (1,015) 
Pfeffer et al. (66) 1987-19911 2,231 Acute MI (SAVE) 35 (789) 
Kennedy et al. (62) 1987-1991 3,549 Post MI (CAST) 27 (718) 
Pashos et al. (67) 1988-1992 65,011 Acute MI 29-38~t 
Scandinavian countries 
Emanuelsson et al. (68) 1986-1987 302 Post MI with CI-iF 46 (139) 
340 Post MI no CHF 71 {241) 
Herlitz et al. (69) 1986-1987 413 Acute MI 68 (282) 
Swedberg et al. (70) 1990-1991 6,090 Acute MI (CONSENSUS 11) 67 (4,073) 
SSSS Group (71) 1988-1994 4,444 Acute M! or Angina (SSSS) 57 (2,524) 
Other countries 
Switzerland 
Burkart et al. (53) 1981-1987 
Germany, Canada, Switzerland 
Willich et al. (72) 1982-1985 
Italy 
Santarelli et al. (73) 1987-1990 
Ambrosioni et al. (74) 1991-1992 
The Netherlands 
Zijlstra et al. (75) 1990-1992 
Mexico 
Hermosillo et al. (76) 1991-1992 
340 Post MI (BASIS) 25 (78) 
1,741 Acute MI (ISAM) 12 (206) 
702 Acute MI (LAPIS) 18 (102) 
1,556 Acute MI (SMILE) 20(311) 
142 Acute MI 33 (47) 
175 Acute MI 33 (58) 
"1975, men 23%, women 17%; 1990, men 60%, women 48%. tPlacebo group of Multicenter Diltiazem Post- 
Infarction Trial (MDPIT). :[:SMS Administrative data base. BASIS = Basel Antiarrhythmic Study of Infarct Survival; 
CAMIAT = Canadian Amiodarone Myocardial Infarction Arrhythmia Trial; CAST = Cardiac Arrhythmia Suppression 
Trial; CHF = congestive heart failure; CONSENSUS = Cooperative North Scandinavian Enalapril Survival Study; 
ISAM = Intravenous Streptokinase inAcute Myocardial Infarction Study; LAPIS = Late Potentials Italian Study; MI = 
myocardial infarction; SAVE = Survival and Ventriculal Enlargement Trial; SOLVD = Studies of Left Ventricalar 
Dysfunction; SMILE = Survival of Myocardial Infarction Long-Term Evaluation Study; SSSS = Scandinavian 
Simvastatin Survival Study. 
such data are confounded by diverse populations from varying 
time trends and do not validate this perspective, nevertheless, 
they present the best overall available perspective ofindividual 
physician prescriptive attitudes regarding beta-blocker ther- 
apy. Others (77-79) have also called attention to the low 
overall use of beta-blocker therapy in North America. What 
differences in clinical training, continuing medical education, 
exposure to commercial influences or selective biases have led 
to such a low overall usage by North Americrn physicians? 
Selective Factors Leading to Nonuse of  
Beta-Blockers 
Undoubtedly, one major reasoa for the nonprescription of
beta-blocker therapy for cardiovascular diseases in North 
America is that internists and family practitioners have re- 
cently been shown (80) to be less aware or less certain than 
cardiologists of cardiovascular medical advances established by 
clinical trials. In a recent survey (80) of physician knowledge 
and attitudes about herapy for acute myocardial infarction in 
the states of New York and Texas, most striking was the finding 
that only -50% of internists and fatally practitioners believed 
that long-term use of beta-blockers definitely improved sur- 
vival compared with 75% of cardiologist=. Whereas the inves- 
tigators cited factors of 1) less knowledge of clinical trials 
pertaining to cardiovascular disease among primary care phy- 
sicians who treat a broader range of clinical problems; 2) 
greater concern about herapeutic complications, uch as con- 
gestive heart failure with beta-blocker therapy; and 3) greater 
caution in accepting new data or changing established patterns 
of treatment as perhaps accounting for these results, they also 
recognized that younger physicians (<40 years of age) were 
either more educated than older physicians with regard to data 
from clinical trials or were more receptive to new standards of 
practice (80,81). Because these latter data were derived from a 
questionnaire and were not actual data taken from medical 
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records, the evidence of Table 1 suggests hat many cardiolo- 
gists in North America "know the right answer" concerning 
beta-blocker therapy but do not necessarily prescribe such 
therapy (80). 
A major factor affecting physician use of beta-blocker 
therapy is a well entrenched, exaggerated concern held by 
many physicians for the therapeutic complications resulting 
from beta-blocker adverse ffects. Such is the case for the 
widespread belief that beta-blocker therapy is detrimental to
patients with left ventricular dysfunction, whereas in reality 
beta-blocker therapy has proved particularly advantageous in 
decreasing mortality, cardiovascular events and new or wors- 
ened congestive heart failure in this subset of patients 
(27,43,45,60-62). Another often maligned adverse ffect of 
beta-blocker therapy both among physicians and visa vis lay 
people is its presumed negative quality of life, resulting from 
increased fatigue, depression or decreased libido. Critical 
analysis of the data relating to the adverse aspects of beta- 
blocker therapy discloses that such beliefs are often exagger- 
ated and cannot be substantiated for the vast majority of 
beta-blocker agents, particularly for those that are betat- 
selective with a long plasma half-life (82-84). 
Although well designed studies using randomized clinical 
trials do not currently exist to critically define these issues, the 
available data overall do not support a major rejection of the 
use of beta-blocker agents on the basis of such adverse ffects 
(82-84). Other areas of clinical concern that may have been 
exaggerated in the thinking of some practicing clinicians is the 
relative contraindication f beta-blocker therapy in patients 
with diabetes mellitus or peripheral vascular disease (85-87). 
The overall data suggest hat for the majority of diabetic 
patients or those with peripheral vascular disease, who often 
have clinical or covert coronary artery disease, the relative 
risk-benefit value of beta-blocker therapy is advantageous 
(85-87). Although caution should be exercised inpatients with 
severe forms of diabetes or vascular disease, the use of low or 
intermediate doses of betarspecific beta-blockers confers a 
clinical benefit that more than outweighs any real or theoretic 
adverse ffect hat may coexist (83,84). 
Finally, it must be realized that commercial influence in the 
lucrative pharmaceutical ompetitive marketplace of the North 
American continent has also contributed tonegative attitudes 
of physicians regarding beta-blocker therapy. Pharmaceutical 
industry competitiveness with tactics of "seeding trials," false 
and misleading claims and "switch campaigns" togain market 
share for a "me too" or "better" product have been reported 
(88). Less substantiated is what we choose to descr:.be as the 
"exaggerated a verse ffects" or "switch class" campaign. It is 
our experience that frequently in the past, all beta-blockers 
were "lumped" by pharmaceutical ompetitors into a pharma- 
cologic category associated with "harmful lipid effects," de- 
creased sexual function," increased heart failure" or "de- 
creased exercise performance." In reality, such claims were 
often exaggerated, unsubstantiated or untrue and rarely ap- 
plied to the majority of beta-blocking agents (83-87). Never- 
theless, it appears that many physicians were susceptible to 
such medical concerns and chose another class of pharmaceu- 
tical agents to avoid potential therapeutic complications. We 
speculate that this "switch class" tactic has in part contributed 
to the documented frequent use of calcium channel blocking 
agents and relative nonuse of beta-blockers in patients with 
ischemic heart disease in North America (63,79,89,90). Fur- 
thermore, beta-blockers have generally been regarded by the 
pharmaceutical industry (from a business perspective) as rela- 
tively low cost agents and, as such, historically have not enjoyed 
widespread promotional efforts of the pharmaceutical industry 
in the form of sponsored national continuing medical educa- 
tional symposia or multinational megatrials. However, these 
latter factors appear to be changing in the present climate of 
clinical guidelines and cost-consciousness with outcome mea- 
surements (90). 
This evolving perspective, however, must also be tempered 
by our recognition of the valid anecdotal experiences of many 
capable clinicians who initially used nonselective beta-blockers 
(frequently in doses now regarded as too high) and encoun- 
tered adverse effects that seeded their personal negative 
attitudes. These negative attitudes, unfortunately, all too often 
were ingrained by the forces described and persisted espite 
the emergence ofclinical trial data to the contrary (67). 
Present Physician Attitudes and Trends 
It is encouraging that physician attitudes appear to be 
changing. The CAST results howed that a significant increase 
in the use of beta-blocker therapy occurred from CAST I (1987 
to 1989, 27%) to CAST II (1989 to 1991, 34%) (62). Another 
recently reported retrospective cohort study (67) of 65,011 
patients treated in 88 hospitals for acute myocardial infarction 
from 1988 to 1992 showed an increase in beta-blocker therapy 
from 29% to 38%. Still another etrospective community- 
based multihospital study (63) of 16 hospitals in Worcester, 
Massachusetts examined time trends of prescribed therapy for 
acute myocardial infarction from 1975 to 1990 and found a 
twofold to threefold increase in the use of beta-blocker therapy 
for both genders (men 23% to 60%; women 17% to 48%). 
Therefore, in North America, physician usage of beta-blocker 
therapy is increasing. 
As suggested by Ayanian et al. (80), a number of factors 
could be anticipated to improve the knowledge and practice 
patterns of physicians. These efforts include a multifaceted 
approach to increasing physician knowledge of clinical trial 
results through continuing-education programs, broader dis- 
semination ofpractice guidelines, more rigorous recertification 
procedures, provision of feedback concerning clinical practices 
and participation in community-based clinical trials (80,89- 
92). The success of such efforts specifically for the appropriate 
utilization of beta-blocker therapy in post-myocardial nfarc- 
tion patients has been preliminarily documented (90), but it 
also seems appropriate for each physician to reflect on his or 
her knowledge of beta-blocker therapy, be aware of the 
influences that have affected his or her attitudes and gain 
insight from this evolving experience. In today's health care 
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marketplace, which is currently undergoing many clinical and 
economic reforms, competitive commercial influences will 
surely contitlue, but the advantages of low cost beta-blocker 
therapy should clearly be recognized. 
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